Eiger snaps up $7.1M to treat hepatitis
Eiger BioPharmaceuticals, developer of treatments for strains of hepatitis, announced that it brought in $7.1 million in first-round funding from InterWest Partners and Vivo Ventures. The Palo Alto, Calif. company will use the new money to push its lead compound — which targets hepatitis C — through its pipeline. It is also working on treatments for hepatitis D and various other viruses, it says.
Eiger spun out from research conducted on hepatitis C at Stanford University. It says the latest round of funding should give it a year’s worth of runway to continue drug testing and refinement.
Next Story: Happy birthday, Yahoo Buzz. Who are you again?
Previous Story: Bloom Energy eyes $150M to commercialize hydrogen fuel cells
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.